3d illustration of molecule model. Science or medical background with molecules and atoms.

C-POLAR Technologies Inc., a bioprotection company dedicated to setting the new standard of health and safety through the protection against viruses and microorganisms, announced positive results from independent studies of C-POLAR’s antimicrobial and antiviral polymer technology completed by a distinguished collective of international research institutions.

Studies conducted at Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, the University of Minnesota, Minneapolis, Tampere University, Tampere, Finland, the Czech Academy of Sciences, Prague, Czechia, and Hong Kong Metropolitan University, Ho Man Tin, Hong Kong — verified that C-POLAR’s proprietary material is extremely effective in arresting, inactivating and eradicating viruses and microorganisms. The independent studies found that the C-POLAR material was able to eradicate more than 99.9 percent of pathogens within 5 minutes and is safe for human applications.

“C-POLAR Technologies is committed to revolutionizing the bioprotection industry with technology that is rooted in significant, validated science,” says Steve Gorlin, Chairman of C-POLAR Technologies, Inc. “These are just the first of the many peer-reviewed scientific articles that we hope demonstrate the testing and re-testing of the C-POLAR material for its efficacy in destroying the many viruses and microorganisms that threaten our very ways of life.”

Massachusetts General Hospital and Harvard Medical School, completed evaluations in April 2022, testing for the eradication of Gram-positive and Gram-negative pathogens (e.g., Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa) over 10 minutes of exposure to C-POLAR iso standards. The study found that C-POLAR treated material significantly reduced pathogens viability, with up to 92 percent reduction in certain pathogens.

Principal investigator during the Massachusetts General Hospital research Dr. Michael Mansour said in his findings, “C-POLAR treated material significantly reduces S. aureus, E. faecalis, Pseudomonas, and E. coli viability. C-POLAR treated fabric demonstrates the eradication of a wide variety of pathogens responsible for the spread of infection on contaminated surfaces.

The utilization of C-POLAR technology has the potential to serve as an essential interrupter to breaking the chain of infectious spread across contaminated surfaces and fabric. The implementation of C-POLAR can reduce infection in many applications (community, hospital, business, school, transportation, and other settings) while improving overall health.”

The University of Minnesota completed investigations in April 2022 and found that C-POLAR percent filters captured and inactivated 99.3 percent of in-flight Bovine Coronavirus in the American Society of Heating, Refrigerating and Air-Conditioning Engineers (ASHRAE) standard wind tunnel tests for in-flight virus inactivation (at 2.5 m/s).

The study from Finland’s Tampere University, completed in April 2021, tested antiviral activity after five minutes in addition to the material’s cytotoxicity on kidney and lung cells. The researchers found that C-POLAR testing materials inactivated more than 99.9 percent of Coxsackievirus B6 and the Human Coronavirus within 5 minutes. The study also concluded that the material was safe for human beings.

Completed in April 2021, the Czech Academy of Sciences tested the antiviral activity at both five and 30 minutes on COVID 19 (SARS-CoV-2), as well as cytotoxicity on kidney cells. The researchers concluded that the material was safe for human beings and that it eliminated 98 percent of COVID-19 within 5 minutes and 99.6 percent within 30 minutes.

Hong Kong Metropolitan University has published a number of articles regarding C-POLAR technology, the most notable being in February 2021, which found that depending on the fabric, C-POLAR testing materials had an antibacterial efficiency ranging from 99-to-99.9999 percent following 60 mechanical washes.

“The scientific rigor behind these studies, and the repetition with which the community has been able to replicate significant results, is the primary motivation for our strong belief in C-POLAR technology to revolutionize the way we think about virus and microorganism protection,” says Jeanne Moldenhauer, chief science officer of C-POLAR Technologies, Inc. “The polarity’s ability to arrest, inactivate and eradicate the pathogens and particles that make up these deadly viruses and microorganisms is vastly more efficient, safe and affordable than other solutions in this industry."